Jeremy Force

Positions:

Assistant Professor of Medicine

Medicine, Medical Oncology
School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

D.O. 2011

University of New England

Internal Medicine Residency

Indiana University, School of Medicine

Hematology/Oncology Fellowship, Medicine

Duke University School of Medicine

Grants:

A Randomized Phase II clinical trial assessing the Efficacy and Safety of MK-3475 (pembrolizumab) in combination with carboplatin and gemcitabine in patients with metastatic triple negative breast cancer

Administered By
Duke Cancer Institute
Awarded By
Fox Chase Cancer Center
Role
Principal Investigator
Start Date
End Date

Phase II Study of Combination Ruxolitinib (INCB018424) with Preoperative Chemotherapy for Triple Negative Inflammatory Breast Cancer protocol # TBCRC 039

Administered By
Duke Cancer Institute
Awarded By
Johns Hopkins University
Role
Principal Investigator
Start Date
End Date

A Phase II randomized study to evaluate the immunologic and antitumor activity of concurrent VRP-HER2 vaccination and Pembrolizumab for patients with advanced HER2-overexpressing breast cancer

Administered By
Duke Cancer Institute
Awarded By
Merck Sharp & Dohme
Role
Principal Investigator
Start Date
End Date

TBCRC 047

Administered By
Duke Cancer Institute
Awarded By
Johns Hopkins University
Role
Principal Investigator
Start Date
End Date

Publications:

Identification of pathogenic ROSI alterations in cell-free DNA (cfDNA) from patients with breast cancer.

Authors
Force, JM; Taylor, ML; Drusbosky, L; Yen, J; Marcom, PK; Anders, CK; Marks, JR
MLA Citation
Force, Jeremy Meyer, et al. “Identification of pathogenic ROSI alterations in cell-free DNA (cfDNA) from patients with breast cancer.Journal of Clinical Oncology, vol. 38, no. 15, 2020.
URI
https://scholars.duke.edu/individual/pub1467186
Source
wos-lite
Published In
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Volume
38
Published Date

Treatment Patterns and Outcomes of Women with Breast Cancer and Supraclavicular Nodal Metastases.

BACKGROUND: In 2002, breast cancer patients with supraclavicular nodal metastases (cN3c) were downstaged from AJCC stage IV to IIIc, prompting management with locoregional treatment. We sought to estimate the impact of multimodal therapy on overall survival (OS) in a contemporary cohort of cN3c patients. METHODS: Women ≥ 18 years with cT1-T4c/cN3c invasive breast cancer who underwent systemic therapy were identified from the 2004-2016 National Cancer Database. We compared three patient cohorts: (a) cN3c + multimodal therapy (systemic therapy, surgery, and radiation); (b) cN3c + non-standard therapy; and, (c) cM1. Logistic regression identified factors associated with receipt of multimodal therapy and Kaplan-Meier was used to estimate unadjusted OS. The Cox proportional hazards model estimated effects of diagnosis and treatment on OS after adjustment. RESULTS: Overall, 1827 (3.7%) patients with cN3c disease and 46,919 (96.3%) cM1 patients were identified. Of cN3c patients, 74.5% (n = 1362) received multimodal therapy and 25.5% (n = 465) received non-standard therapy; receipt of multimodal therapy was associated with improved 5-year OS (multimodal: 59% vs. M1: 28% vs. non-standard: 28%, log-rank p < 0.001). Adjusting for covariates, non-standard therapy was associated with an increased risk of death compared with receipt of multimodal therapy (HR 2.20, 95% CI 1.71-2.83, p < 0.001). Private insurance was the only patient characteristic associated with a greater likelihood of receiving multimodal therapy (OR 2.81; 95% CI, 1.64-4.82; p < 0.001). CONCLUSION: Women with cN3c breast cancer who received multimodal therapy demonstrated improved overall survival when compared with patients undergoing non-standard therapy and those with metastatic (M1) disease. Although selection bias may contribute to worse overall survival among cN3c patients undergoing non-standard therapy, national guidelines should encourage locoregional treatment in carefully selected patients.
Authors
Tamirisa, NP; Ren, Y; Campbell, BM; Thomas, SM; Fayanju, OM; Plichta, JK; Rosenberger, LH; Force, J; Hyslop, T; Hwang, ES; Greenup, RA
MLA Citation
Tamirisa, Nina P., et al. “Treatment Patterns and Outcomes of Women with Breast Cancer and Supraclavicular Nodal Metastases.Ann Surg Oncol, vol. 28, no. 4, Apr. 2021, pp. 2146–54. Pubmed, doi:10.1245/s10434-020-09024-1.
URI
https://scholars.duke.edu/individual/pub1460793
PMID
32946012
Source
pubmed
Published In
Annals of Surgical Oncology
Volume
28
Published Date
Start Page
2146
End Page
2154
DOI
10.1245/s10434-020-09024-1

Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.

OPINION STATEMENT: Immune checkpoint blockade (ICB) has revolutionized the treatment landscape across multiple solid tumor types. In triple-negative breast cancer (TNBC), clinical benefit for the addition of ICB to chemotherapy has been shown in both the metastatic and early stage disease settings. A minority of patients with TNBC will truly benefit from ICB, with many tumors unlikely to respond, and ICB can cause additional toxicities for patients to incur. In clinical practice, ICB-based regimens are emerging as standard-of-care treatment options in TNBC subpopulations. Atezolizumab in combination with nab-paclitaxel is recommended as first-line treatment for patients with PD-L1-positive metastatic TNBC. Clinical trials are needed to confirm this benefit and evaluate if additional biomarkers may allow for improved patient selection. Trials investigating ICB in early-stage breast cancer show promise for the benefit of combination ICB with neoadjuvant chemotherapy. However, longer follow-up is required before ICB can be considered as standard-of-care treatment in the early stage setting. In both metastatic and early stage TNBC, novel biomarkers to improve patient selection are now under investigation. These include multiplex IHC to profile immune cell subtypes (such as tumor infiltrating lymphocytes) or RNA gene expression profiling to detect signatures suggestive of a T-cell-inflamed microenvironment. Detecting somatic mutations through tumor next-generation DNA sequencing may predict resistance mechanisms or suggest sensitivity to ICB monotherapy or in combination with other forms of systemic therapy. These biomarker platforms may allow for a more granular analysis of immune activity and should be further investigated in prospective studies with the aim of personalizing ICB-focused therapies in TNBC.
Authors
Isaacs, J; Anders, C; McArthur, H; Force, J
MLA Citation
Isaacs, James, et al. “Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.Curr Treat Options Oncol, vol. 22, no. 5, Mar. 2021, p. 38. Pubmed, doi:10.1007/s11864-021-00833-4.
URI
https://scholars.duke.edu/individual/pub1476464
PMID
33743085
Source
pubmed
Published In
Current Treatment Options in Oncology
Volume
22
Published Date
Start Page
38
DOI
10.1007/s11864-021-00833-4

Abstract P1-06-02: Characterization of gene- and sample-level APOBEC mutagenesis enrichment with respect to intrinsic subtypes, tumor mutational burden, and immune composition in breast cancer

Authors
Force, J; Qin, X; Zhang, D; Marcom, PK; Marks, J; Taylor, ML; Anders, C; Owzar, K; Xie, J
MLA Citation
Force, Jeremy, et al. “Abstract P1-06-02: Characterization of gene- and sample-level APOBEC mutagenesis enrichment with respect to intrinsic subtypes, tumor mutational burden, and immune composition in breast cancer.” Poster Session Abstracts, American Association for Cancer Research, 2020. Crossref, doi:10.1158/1538-7445.sabcs19-p1-06-02.
URI
https://scholars.duke.edu/individual/pub1442732
Source
crossref
Published In
Poster Session Abstracts
Published Date
DOI
10.1158/1538-7445.sabcs19-p1-06-02

Abstract P3-08-10: Characterization of oncotype DX recurrence score and chemotherapy utilization patterns in young women (≤40) with early stage ER+/HER-, lymph node negative breast cancer

MLA Citation
Sammons, Sarah, et al. “Abstract P3-08-10: Characterization of oncotype DX recurrence score and chemotherapy utilization patterns in young women (≤40) with early stage ER+/HER-, lymph node negative breast cancer.” Poster Session Abstracts, American Association for Cancer Research, 2020. Crossref, doi:10.1158/1538-7445.sabcs19-p3-08-10.
URI
https://scholars.duke.edu/individual/pub1442733
Source
crossref
Published In
Poster Session Abstracts
Published Date
DOI
10.1158/1538-7445.sabcs19-p3-08-10

Research Areas:

APOBEC
BRCA genes
Breast--Cancer--Immunotherapy
Cancer/testis Antigens
Homologous Recombination
Inflammatory Breast Cancer
Nanostring
Tumor Immune Microenvironment
Tumor Infiltrating Lymphocytes
X Chromosome Inactivation
X chromosome--Abnormalities